Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
STARLIX is an oral small-molecule tablet approved by Novartis in December 2000 for diabetes management. The drug's mechanism of action and specific indications are not disclosed in available data. It represents a legacy product in Novartis's endocrinology portfolio.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a mature brand team focused on lifecycle management rather than expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked job openings suggest STARLIX is a stable, mature product with minimal hiring. Roles on this brand focus on defensive market management and margin protection rather than growth innovation. This is a consolidation opportunity for professionals seeking stability, but not ideal for career acceleration.
Worked on STARLIX at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.